Drugs / ORB-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05947474 | Aug 2023 → May 2026 | cancer | Orionis Biosciences Inc | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-15 | Orionis Biosciences Inc | Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors orionisbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORB-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05947474 ↗ |
| Action | Activate | “confers full activation in cis” NCT05947474 ↗ |